ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1083

How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus?

Alexjandro Daviano1, Vijay R. Nadipelli2, Yihua Xu1, Karen Worley2, Shireen Haq1, Josephine Ohioma3, Jeffrey J. Ellis2, Brandon T. Suehs1 and S. Sam Lim4, 1Humana Healthcare Research, Inc., Louisville, KY, 2GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, 3GSK, US Medical Affairs, Philadelphia, PA, 4Emory University School of Medicine, Atlanta, GA

Meeting: ACR Convergence 2025

Keywords: Disparities, Health Services Research, psychosocial factors, socioeconomic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1055–1087) Healthcare Disparities in Rheumatology Posters

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Management of patients with SLE should consider social determinants of health (SDoH) and their impact on access, treatment, and patient outcomes; however, such a holistic approach is not routinely studied or adopted in clinical practice.1 To close this knowledge gap, we assessed patient characteristics including SDoH, disease burden and clinical outcomes, and healthcare resource use (HCRU) among adult Medicare Advantage (MA) plan enrollees with SLE.

Methods: This retrospective analysis (GSK Study 222168) used administrative claims data supplemented with patient- and community-level measures of SDoH. Humana MA enrollees 18–89 years of age (YOA) with SLE (with or without LN) and enrolled during the 2023 calendar year were included. Diagnosis of SLE was required on ≥1 medical claim during 2023 and ≥1 diagnosis prior to 2023. Measures of disease burden, medication use, and HCRU were based on claims data. Measures of social risk (e.g. low-income subsidy [LIS], dual eligibility [DE], disability) were based on enrollment file data. Community-level measures of social risk (e.g. public assistance, educational attainment) were based on publicly available data sources. Analyses were descriptive.

Results: Among 20,188 patients with SLE identified (90.3% female, 30.7% of Black race), 76.2% had a Health Equity Index and 46.3% had a DE/LIS status. Approximately half of MA enrollees were < 65 YOA (45.5%). Compared with enrollees ≥65 YOA, < 65-year-olds had elevated social risk factors, with nearly all (99.7%) having disability and DE/LIS status (Table 1). MA enrollees < 65 YOA also tended to reside in communities with greater social risk (lower income and educational attainment, higher unemployment, greater use of public assistance; Table 1). Moderate/severe SLE was more common among enrollees < 65 YOA (82.8% vs 78.4%), who also had higher treatment rates with SLE medications compared with enrollees ≥65 YOA (Table 2).Disability as the original reason for MA qualification was common overall (67.7%), including 98.3% of < 65 YOA and 42.2% of ≥65 YOA enrollees (Table 1). Among enrollees ≥65 YOA who originally qualified for MA based on disability, social risk factors, disease severity, SLE medication use, and HCRU were generally greater than for the enrollees ≥65 YOA overall (Table 1 and 2). Enrollees < 65 YOA were more likely to visit a rheumatologist (36.5% vs 30.3% of those ≥65 YOA) or a nephrologist (7.2% vs 5.0% of those ≥65 YOA) for an SLE-related visit (Table 2). Among the enrollees < 65 YOA who visited a rheumatologist or nephrologist, 46.1%, 70.7%, and 14.2% received immunosuppressant, antimalarial, and biologic treatment, respectively.

Conclusion: We observed substantial social risk factors among MA enrollees with SLE, with disability being the dominant reason for MA qualification. SLE severity, treatment patterns, and HCRU varied between ≥65 and < 65-year-olds. Interventions to address the unmet needs should consider the burden of SDoH and diversity of the MA SLE population. Further research is needed to identify and evaluate specific health-related unmet needs of this population, potential interventions, and impact on patient outcomes.Funding: GSKReference1Lim SS et al. Arthritis Care Res 2025 (in press)

Supporting image 1Table 1. Patient SDoH characteristics stratified by age and qualification for MA on the basis of disability.

*Enrollees ≥65 YOA who originally qualified for MA based on disability; †a higher ADI score is indicative of high levels of area deprivation and lower score is indicative of area affluence; ‡approximately 91% of patients were matched to the AHRQ SDoH database at census tract level, and the rest were matched at zip code level. There were 72 observations with missing value on median household income, 91 on percentage of families with children that are single-parent families. The rest of the AHRQ measures had 0–5 missing values; §percentage below national median; ǁpercentage above national median.

ADI, area deprivation index; AHRQ, Agency for Healthcare Research and Quality; CMS, Centers for Medicare and Medicaid Services; HEI, Health Equity Index; SD, standard deviation.

Supporting image 2Table 2. Patient disease and treatment characteristics, and HCRU, stratified by age and qualification for MA on the basis of disability.

*Enrollees ≥65 YOA who originally qualified for MA based on disability; †PCP included family medicine, internal medicine, and general practice.

ED, emergency department; PCP, primary care provider.


Disclosures: A. Daviano: Humana Healthcare Research, 3; V. Nadipelli: GSK, 12,, 3; Y. Xu: Humana Healthcare Research, 12,, 3; K. Worley: GSK, 12,, 3; S. Haq: Humana Healthcare Research, 3; J. Ohioma: GSK, 12,, 3; J. Ellis: GSK, 12,, 3, 8; B. Suehs: Humana Healthcare Research, 12,, 3; S. Lim: Accordant, 2, AstraZeneca, 2, Biogen, 5, BMS, 5, Genentech, 2, Gilead, 5, GSK, 2, Novartis, 5, UCB, 5.

To cite this abstract in AMA style:

Daviano A, Nadipelli V, Xu Y, Worley K, Haq S, Ohioma J, Ellis J, Suehs B, Lim S. How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus? [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/how-do-social-determinants-of-health-differ-across-age-and-disability-groups-among-adult-medicare-advantage-enrollees-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-do-social-determinants-of-health-differ-across-age-and-disability-groups-among-adult-medicare-advantage-enrollees-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology